Smad7 induces tumorigenicity by blocking TGF-β-induced growth inhibition and apoptosis

Sunil Krishna Halder, R. Daniel Beauchamp, Pran K. Datta

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Smad proteins play a key role in the intracellular signaling of the transforming growth factor β (TGF-β) superfamily of extracellular polypeptides that initiate signaling to regulate a wide variety of biological processes. The inhibitory Smad, Smad7, has been shown to function as intracellular antagonists of TGF-β family signaling and is upregulated in several cancers. To determine the effect of Smad7-mediated blockade of TGF-β signaling, we have stably expressed Smad7 in a TGF-β-sensitive, well-differentiated, and non-tumorigenic cell line, FET, that was derived from human colon adenocarcinoma. Smad7 inhibits TGF-β-induced transcriptional responses by blocking complex formation between Smad 2/3 and Smad4. While Smad7 has no effect on TGF-β-induced activation of p38 MAPK and ERK, it blocks the phosphorylation of Akt by TGF-β and enhances TGF-β-induced phosphorylation of c-Jun. FET cells expressing Smad7 show anchorage-independent growth and enhance tumorigenicity in athymic nude mice. Smad7 blocks TGF-β-induced growth inhibition by preventing TGF-β-induced G1 arrest. Smad7 inhibits TGF-β-mediated downregulation of c-Myc, CDK4, and Cyclin D1, and suppresses the expression of p21Cip1. As a result, Smad7 inhibits TGF-β-mediated downregulation of Rb phosphorylation. Furthermore, Smad7 inhibits the apoptosis of these cells. Together, Smad7 may increase the tumorigenicity of FET cells by blocking TGF-β-induced growth inhibition and by inhibiting apoptosis. Thus, this study provides a mechanism by which a portion of human colorectal tumors may become refractory to tumor-suppressive actions of TGF-β that might result in increased tumorigenicity.

Original languageEnglish (US)
Pages (from-to)231-246
Number of pages16
JournalExperimental Cell Research
Volume307
Issue number1
DOIs
StatePublished - Jul 1 2005

Fingerprint

Transforming Growth Factors
Apoptosis
Growth
Phosphorylation
Nude Mice
Down-Regulation
Smad Proteins
Biological Phenomena
Cyclin D1
p38 Mitogen-Activated Protein Kinases
Colorectal Neoplasms
Neoplasms
Colon
Adenocarcinoma

Keywords

  • Apoptosis
  • Colon cancer
  • FET
  • Smad7
  • TGF-β (transforming growth factor-β)
  • Tumorigenicity

ASJC Scopus subject areas

  • Cell Biology

Cite this

Smad7 induces tumorigenicity by blocking TGF-β-induced growth inhibition and apoptosis. / Halder, Sunil Krishna; Beauchamp, R. Daniel; Datta, Pran K.

In: Experimental Cell Research, Vol. 307, No. 1, 01.07.2005, p. 231-246.

Research output: Contribution to journalArticle

Halder, Sunil Krishna ; Beauchamp, R. Daniel ; Datta, Pran K. / Smad7 induces tumorigenicity by blocking TGF-β-induced growth inhibition and apoptosis. In: Experimental Cell Research. 2005 ; Vol. 307, No. 1. pp. 231-246.
@article{506cb654404948158e9de9fabfc34d14,
title = "Smad7 induces tumorigenicity by blocking TGF-β-induced growth inhibition and apoptosis",
abstract = "Smad proteins play a key role in the intracellular signaling of the transforming growth factor β (TGF-β) superfamily of extracellular polypeptides that initiate signaling to regulate a wide variety of biological processes. The inhibitory Smad, Smad7, has been shown to function as intracellular antagonists of TGF-β family signaling and is upregulated in several cancers. To determine the effect of Smad7-mediated blockade of TGF-β signaling, we have stably expressed Smad7 in a TGF-β-sensitive, well-differentiated, and non-tumorigenic cell line, FET, that was derived from human colon adenocarcinoma. Smad7 inhibits TGF-β-induced transcriptional responses by blocking complex formation between Smad 2/3 and Smad4. While Smad7 has no effect on TGF-β-induced activation of p38 MAPK and ERK, it blocks the phosphorylation of Akt by TGF-β and enhances TGF-β-induced phosphorylation of c-Jun. FET cells expressing Smad7 show anchorage-independent growth and enhance tumorigenicity in athymic nude mice. Smad7 blocks TGF-β-induced growth inhibition by preventing TGF-β-induced G1 arrest. Smad7 inhibits TGF-β-mediated downregulation of c-Myc, CDK4, and Cyclin D1, and suppresses the expression of p21Cip1. As a result, Smad7 inhibits TGF-β-mediated downregulation of Rb phosphorylation. Furthermore, Smad7 inhibits the apoptosis of these cells. Together, Smad7 may increase the tumorigenicity of FET cells by blocking TGF-β-induced growth inhibition and by inhibiting apoptosis. Thus, this study provides a mechanism by which a portion of human colorectal tumors may become refractory to tumor-suppressive actions of TGF-β that might result in increased tumorigenicity.",
keywords = "Apoptosis, Colon cancer, FET, Smad7, TGF-β (transforming growth factor-β), Tumorigenicity",
author = "Halder, {Sunil Krishna} and Beauchamp, {R. Daniel} and Datta, {Pran K.}",
year = "2005",
month = "7",
day = "1",
doi = "10.1016/j.yexcr.2005.03.009",
language = "English (US)",
volume = "307",
pages = "231--246",
journal = "Experimental Cell Research",
issn = "0014-4827",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Smad7 induces tumorigenicity by blocking TGF-β-induced growth inhibition and apoptosis

AU - Halder, Sunil Krishna

AU - Beauchamp, R. Daniel

AU - Datta, Pran K.

PY - 2005/7/1

Y1 - 2005/7/1

N2 - Smad proteins play a key role in the intracellular signaling of the transforming growth factor β (TGF-β) superfamily of extracellular polypeptides that initiate signaling to regulate a wide variety of biological processes. The inhibitory Smad, Smad7, has been shown to function as intracellular antagonists of TGF-β family signaling and is upregulated in several cancers. To determine the effect of Smad7-mediated blockade of TGF-β signaling, we have stably expressed Smad7 in a TGF-β-sensitive, well-differentiated, and non-tumorigenic cell line, FET, that was derived from human colon adenocarcinoma. Smad7 inhibits TGF-β-induced transcriptional responses by blocking complex formation between Smad 2/3 and Smad4. While Smad7 has no effect on TGF-β-induced activation of p38 MAPK and ERK, it blocks the phosphorylation of Akt by TGF-β and enhances TGF-β-induced phosphorylation of c-Jun. FET cells expressing Smad7 show anchorage-independent growth and enhance tumorigenicity in athymic nude mice. Smad7 blocks TGF-β-induced growth inhibition by preventing TGF-β-induced G1 arrest. Smad7 inhibits TGF-β-mediated downregulation of c-Myc, CDK4, and Cyclin D1, and suppresses the expression of p21Cip1. As a result, Smad7 inhibits TGF-β-mediated downregulation of Rb phosphorylation. Furthermore, Smad7 inhibits the apoptosis of these cells. Together, Smad7 may increase the tumorigenicity of FET cells by blocking TGF-β-induced growth inhibition and by inhibiting apoptosis. Thus, this study provides a mechanism by which a portion of human colorectal tumors may become refractory to tumor-suppressive actions of TGF-β that might result in increased tumorigenicity.

AB - Smad proteins play a key role in the intracellular signaling of the transforming growth factor β (TGF-β) superfamily of extracellular polypeptides that initiate signaling to regulate a wide variety of biological processes. The inhibitory Smad, Smad7, has been shown to function as intracellular antagonists of TGF-β family signaling and is upregulated in several cancers. To determine the effect of Smad7-mediated blockade of TGF-β signaling, we have stably expressed Smad7 in a TGF-β-sensitive, well-differentiated, and non-tumorigenic cell line, FET, that was derived from human colon adenocarcinoma. Smad7 inhibits TGF-β-induced transcriptional responses by blocking complex formation between Smad 2/3 and Smad4. While Smad7 has no effect on TGF-β-induced activation of p38 MAPK and ERK, it blocks the phosphorylation of Akt by TGF-β and enhances TGF-β-induced phosphorylation of c-Jun. FET cells expressing Smad7 show anchorage-independent growth and enhance tumorigenicity in athymic nude mice. Smad7 blocks TGF-β-induced growth inhibition by preventing TGF-β-induced G1 arrest. Smad7 inhibits TGF-β-mediated downregulation of c-Myc, CDK4, and Cyclin D1, and suppresses the expression of p21Cip1. As a result, Smad7 inhibits TGF-β-mediated downregulation of Rb phosphorylation. Furthermore, Smad7 inhibits the apoptosis of these cells. Together, Smad7 may increase the tumorigenicity of FET cells by blocking TGF-β-induced growth inhibition and by inhibiting apoptosis. Thus, this study provides a mechanism by which a portion of human colorectal tumors may become refractory to tumor-suppressive actions of TGF-β that might result in increased tumorigenicity.

KW - Apoptosis

KW - Colon cancer

KW - FET

KW - Smad7

KW - TGF-β (transforming growth factor-β)

KW - Tumorigenicity

UR - http://www.scopus.com/inward/record.url?scp=19544368435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19544368435&partnerID=8YFLogxK

U2 - 10.1016/j.yexcr.2005.03.009

DO - 10.1016/j.yexcr.2005.03.009

M3 - Article

C2 - 15922743

AN - SCOPUS:19544368435

VL - 307

SP - 231

EP - 246

JO - Experimental Cell Research

JF - Experimental Cell Research

SN - 0014-4827

IS - 1

ER -